Moreover, the mechanistic rationale for using polatuzumab vedotin in NHL is supported by preclinical evidence demonstrating its selective affinity for CD79B, which is ubiquitously expressed on malignant B cells but limited in normal tissues. This evidence concerns the gene CD79B and non-Hodgkin lymphoma.